Akt signaling pathway: A target for radiosensitizing human malignant glioma

Neuro-Oncology

Volumn 12, Issue 5, 2010, Pages 434-443

  Chautard, Emmanuel ^a   Loubeau, Gaëlle ^a   Tchirkov, Andreï ^a   Chassagne, Jacques ^a   Vermot Desroches, Claudine ^b   Morel, Laurent ^c   Verrelle, Pierre ^a  

^a CENTRE JEAN PERRIN   (France)

^b EUSA Pharma   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Akt signaling pathway; Human malignant glioma; Intrinsic radioresistance; STAT3 signaling pathway

Indexed keywords

JSI 124; MORINAMIDE; PROTEIN INHIBITOR; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL SURVIVAL; DOWN REGULATION; ENZYME ACTIVATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; BRAIN TUMOR; GLIOMA; METABOLISM; PHYSIOLOGY; RADIATION DOSE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77954710908     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop059     Document Type: Article

References (49)

1. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;91:1382-1390
2. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol. 2001;13: 160-166
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl). 2005;109:93-108
4. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol. 1998;44: 691-695
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996
6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-1329
7. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725-1731
8. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991;64:769-774
9. Shannon AM, Williams KJ. Antiangiogenics and radiotherapy. J Pharm Pharmacol. 2008;60:1029-1036
10. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the microregional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol. 2003;67: 3-15
11. De Ridder M, Verovski VN, Darville MI, et al. Macrophages enhance the radiosensitizing activity of lipid A: a novel role for immune cells in tumor cell radioresponse. Int J Radiat Oncol Biol Phys. 2004;60:598-606
12. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059
13. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006;66:3963-3966
14. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-2512
15. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926-1933
16. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002;21:8404-8413
17. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs. 2007;18:861-874
18. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97-105
19. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem. 2008;15:834-843
20. Kau TR, Schroeder F, Ramaswamy S, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003;4:463-476
21. Han H, Shin SW, Seo CY, et al. 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis. 2007;12:2101-2114
22. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003;63:1270-1279
23. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008;14:6042-6054
24. Delmas C, Heliez C, Cohen-Jonathan E, et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer. 2002;100:43-48
25. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res. 2005;65:4368-4375
26. Russell JS, Lang FF, Huet T, et al. Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res. 1999;59:5239-5244
27. Casper D, Lekhraj R, Yaparpalvi US, et al. Acetaminophen selectively reduces glioma cell growth and increases radiosensitivity in culture. J Neurooncol. 2000;46:215-229
28. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261-269
29. Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651-662
30. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90:1297-1301
31. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433-439
32. Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-2-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following Ionizing radiation. J Biol Chem. 2007;282:21206-21212
33. Toulany M, Dittmann K, Fehrenbacher B, Schaller M, Baumann M, Rodemann HP. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst). 2008;7:1746-1756
34. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells. 2008;26:3027-3036
35. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22:436-448
36. Norman BH, Shih C, Toth JE, et al. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem. 1996;39:1106-1111
37. Gupta AK, Cerniglia GJ, Mick R, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys. 2003;56:846-853
38. Chen JS, Zhou LJ, Entin-Meer M, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 30-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008;7:841-850
39. Jiang Z, Pore N, Cerniglia GJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2007;67:4467-4473
40. Su Y, Li G, Zhang X, et al. JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biol Ther. 2008;7:1243-1249
41. Fujita M, Zhu X, Sasaki K, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol. 2008;180:2089-2098
42. de la Iglesia N, Konopka G, Puram SV, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008;22:449-462
43. de la Pena L, Burgan WE, Carter DJ, et al. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther. 2006;5:1504-1510
44. Tchirkov A, Khalil T, Chautard E, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 2007;96:474-476
45. Tchirkov A, Rolhion C, Bertrand S, Dore JF, Dubost JJ, Verrelle P. IL-6 gene amplification and expression in human glioblastomas. Br J Cancer. 2001;85:518-522
46. Chakravarti A, Seiferheld W, Tu X, et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:318-327
47. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15:1311-1333
48. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway, radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol. 2009;4:761-767
49. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007;3:682-693